Neuroethics

, Volume 5, Issue 2, pp 173–184 | Cite as

Ethical Considerations in the Framing of the Cognitive Enhancement Debate

Original Paper

Abstract

Over the past few years the use of stimulants such as methylphenidate and modafinil among the student population has attracted considerable debate in the pages of bioethics journals. Under the rubric of cognitive enhancement, bioethicists have discussed this use of stimulants—along with future technologies of enhancement—and have launched a sometimes forceful debate of such practices. In the following paper, it is argued that even if we focus solely upon current practices, the term cognitive enhancement encompasses a wide range of ethical considerations that can usefully be addressed without the need for speculation. In taking this position it is suggested that we divide cognitive enhancement into a series of empirically-constructed frameworks—medical risks and benefits, self-medication and under-prescription, prescription drug abuse and over-medication, and finally, the intention to cognitively enhance. These are not mutually exclusive frameworks, but provide a way in which to identify the scope of the issue at hand and particular ethical and medical questions that may be relevant to enhancement. By a process of elimination it is suggested that we can indeed talk of cognitive enhancement as an observable set of practices. However, in doing so we should be aware of how academic commentaries and discussion may be seen as both capturing reality and reifying cognitive enhancement as an entity.

Keywords

Bioethics Cognitive enhancement Framing Stimulants 

Notes

Acknowledgements

The author would like to thank Professor Wayne Hall of the Addiction Neuroethics unit University of Queensland for comments on an earlier draft of this paper.

Funding

Research funded by Canadian Institutes of Health Research, NNF 80045, States of Mind: Emerging Issues in Neuroethics

Conflict of Interest

None Declared

References

  1. 1.
    Baylis, F., and J.S. Robert. 2004. The inevitability of genetic enhancement technologies. Bioethics 18(1): 1–26.CrossRefGoogle Scholar
  2. 2.
    Bostrom, Nick, and Anders Sandberg. 2009. Cognitive enhancement: Methods, ethics, regulatory challenges. Science & Engineering Ethics 15(3): 311–341.CrossRefGoogle Scholar
  3. 3.
    Cakic, V. 2009. Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology. Journal of Medical Ethics 35(10): 611–615.CrossRefGoogle Scholar
  4. 4.
    Chatterjee, A. 2006. The promise and predicament of cosmetic neurology. Journal of Medical Ethics 32: 110e13.Google Scholar
  5. 5.
    Farah, Martha J., Judy Illes, Robert Cook-Deegan, Howard Gardner, Eric Kandel, Patricia King, Eric Parens, Barbara Sahakian, and Paul Root Wolpe. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews: Neuroscience: 421–5.Google Scholar
  6. 6.
    Sahakian, B.J., and S. Morein-Zamir. 2011. Neuroethical issues in cognitive enhancement. Journal of Psychopharmacology 25(2): 197–204.CrossRefGoogle Scholar
  7. 7.
    Jones, D.G. 2006. Enhancement: Are ethicists excessively influenced by baseless speculations? Medical Humanities 32(2): 77–81.CrossRefGoogle Scholar
  8. 8.
    Hall, W.D., and J.C. Lucke. 2010. The enhancement use of neuropharmaceuticals: More scepticism and caution needed. Addication 105: 2041–2043.CrossRefGoogle Scholar
  9. 9.
    Williams, S.J., and P. Martin. 2009. Risks and benefits may turn out to be finely balanced. Nature 457: 532.CrossRefGoogle Scholar
  10. 10.
    Banjo, O.C., R. Nadler, and P.B. Reiner. 2010. Physician attitudes towards pharmacological cognitive enhancement: Safety concerns are paramount. PLoS One 5(12). doi:10.1371/journal.pone.0014322.
  11. 11.
    Hotze, T.D., K. Shah, E.E. Anderson, and M.K. Wynia. 2011. “Doctor, would you prescribe a pill to help me…?” A national survey of physicians on using medicine for human enhancement. American Journal of Bioethics 11(1): 3–13.CrossRefGoogle Scholar
  12. 12.
    Larriviere, Dan J.D., Michael A.F.A.A.N. Williams, Matt F.A.A.N. Rizzo, and Richard J.L.L.B. Bonnie. 2009. Responding to requests from adult patients for neuroenhancements: Guidance of the ethics, law and humanities committee. Neurology 73(17): 1406–1412.CrossRefGoogle Scholar
  13. 13.
    Farah, M.J., C. Haimm, G. Sankoorikal, and A. Chatterjee. 2009. When we enhance cognition with adderall, do we sacrifice creativity? A preliminary study. Psychopharmacology. 202(1): 541–547.CrossRefGoogle Scholar
  14. 14.
    BMA. Boosting your Brainpower: Ethical Aspects of Cognitive Enhancement. 2007. available from http://www.bma.org.uk/images/Boosting_brainpower_tcm41-147266.pdf, [accessed 21 February 2011].
  15. 15.
    Advokat, C.D., D. Guidry, and L. Martino. 2008. Licit and illicit use of medications for attention-deficit hyperactivity disorder in undergraduate college students. Journal of American College Health 56(6): 601–606.CrossRefGoogle Scholar
  16. 16.
    Barrett, S.P., C. Darredeau, L.E. Bordy, and R.O. Pihl. 2005. Characteristics of methylphenidate misuse in a university student sample. Canadian Journal of Psychiatry 50(8): 457–461.Google Scholar
  17. 17.
    McCabe, S.E., J.R. Knight, C.J. Teter, and H. Wechsler. 2005. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100(1): 96–106.CrossRefGoogle Scholar
  18. 18.
    Teter, C.J., S.E. McCabe, J.A. Cranford, C.J. Boyd, and S.K. Guthrie. 2005. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. Journal of American College Health 53(6): 253–262.CrossRefGoogle Scholar
  19. 19.
    White, B.P., K.A. Becker-Blease, and K. Grace-Bishop. 2006. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. Journal of American College Health 54(5): 261–268.CrossRefGoogle Scholar
  20. 20.
    Outram, S.M. 2010. The use of methylphenidate among students: The future of enhancement? Journal of Medical Ethics. 36(4): 198–202.CrossRefGoogle Scholar
  21. 21.
    Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 19752009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2.Google Scholar
  22. 22.
    Maher, B. 2008. Poll results: Look who's doping. Nature 452: 674–675.CrossRefGoogle Scholar
  23. 23.
    Johnston, L. D., O’Malley, P. M., Bachman, J. G., and Schulenberg, J. E. 2010. Monitoring the Future national survey results on drug use, 19752009: Volume II, College students and adults ages 19–50 (NIH Publication No. 10–7585). Bethesda, MD:National Institute on Drug Abuse. Table 2–2 p.47.Google Scholar
  24. 24.
    Rabiner, D.L., A.D. Anastopoulos, E. Jane Costello, R.H. Hoyle, S.E. McCabe, and H. Scott Swartzwelder. 2009. Motives and perceived consequences of nonmedical ADHD medication use by college students. Journal of Attention Disorders 13(3): 259–270.CrossRefGoogle Scholar
  25. 25.
    Repantis, Dimitris, Schlattmann Peter, Laisney Oona, and Heuser Isabella. 2010. Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review. Pharmacological Research 62(3): 187–206.CrossRefGoogle Scholar
  26. 26.
    Efron, Daryl, Frederick Jarman, and Melinda Barker. 1997. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial. Pediatrics 100(4): 662–666.CrossRefGoogle Scholar
  27. 27.
    Godfrey, J. 2009. Safety of therapeutic methylphenidate in adults: A systematic review of the evidence. Journal of Psychopharmacology 23(2): 194–205.CrossRefGoogle Scholar
  28. 28.
    Kooij, J.J.S., H. Burger, A.M. Boonstra, P.D. Van Der Linden, L.E. Kalma, and J.K. Buitelaar. 2004. Efficacy and Safety Of Methylphenidate in 45 Adults With attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial. Psychological Medicine 34(6): 973–982.CrossRefGoogle Scholar
  29. 29.
    Kollins, S.H., E.K. MacDonald, and C.R. Rush. 2001. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacology, Biochemistry and Behavior 68: 611–627.CrossRefGoogle Scholar
  30. 30.
    Schermer, M., I. Bolt, R. de Jong, and B. Olivier. 2009. The future of psychopharmacological enhancements: Expectations and policies. Neuroethics 2 (2): 75–87Google Scholar
  31. 31.
    Randall, Delia C., John M. Shneerson, and Sandra E. File. 2005. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacology Biochemistry and Behavior 82(1): 133–139.CrossRefGoogle Scholar
  32. 32.
    Partnership Attitude Tracking Study (Teens) DEA. 2009. Available from: www.getsmartaboutdrugs.com/identify/partnership_attitudetracking_study_teens.html. [Accessed 8 June, 2011].
  33. 33.
    Poulin, C. 2007. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: Connecting the dots. Addiction 102(5): 740–751.CrossRefGoogle Scholar
  34. 34.
    Wilens, T.E., L.A. Adler, J. Adams, S. Sgambati, J. Rotrosen, R. Sawtelle, L. Utzinger, and S. Fusillo. 2008. Misuse and diversion of stimulants prescribed for ADHD: A systematic review of the literature. Journal of the American Academy of Child & Adolescent Psychiatry 47(1): 21–31.CrossRefGoogle Scholar
  35. 35.
    DSM-IV-TR® Diagnostic and Statistical Manual of Mental Disorders. Available at: http://www.psychiatryonline.com/content.aspx?aID=7721&searchStr=attention-deficit%2fhyperactivity+disorder [accessed 12 June, 20111]
  36. 36.
    Kessler, Ronald C., Lenard Adler, Russell Barkley, Joseph Biederman, C.Keith Conners, Olga Demler, and Stephen V. Faraone. 2006. The prevalence and correlates of adult ADHD in the united states: Results from the national comorbidity survey replication. American Journal of Psychiatry 163: 716–723.CrossRefGoogle Scholar
  37. 37.
    Faraone, S.V., and J. Biederman. 2005. What is the prevalence of adult ADHD? results of a population screen of 966 adults. Journal of Attention Disorders 9(2): 384–391.CrossRefGoogle Scholar
  38. 38.
    Fayyad, J., R. De Graaf, R. Kessler, J. Alonso, M. Angermeyer, K. Demyttenaere, G. De Girolamo, et al. 2007. Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. The British Journal of Psychiatry 190(5): 402–409.CrossRefGoogle Scholar
  39. 39.
    Racine, E., and C. Forlini. 2010. Cognitive enhancement, lifestyle choice or misuse of prescription drugs? Neuroethics 3(1): 1–4.CrossRefGoogle Scholar
  40. 40.
    INCB. 2009. International Narcotics Control Board Report. Available: http://www.incb.org/pdf/annual-report/2009/en/AR_09_English.pdf (accessed Jan 20, 2011).
  41. 41.
    Boyd, C.J., S.E. McCabe, J.A. Cranford, and A. Young. 2007. Prescription drug abuse and diversion among adolescents in a southeast michigan school district. Archives of Pediatrics Adolescent Medicine 161(3): 276–281.CrossRefGoogle Scholar
  42. 42.
    Fischer, B., M. Bibby, and M. Bouchard. 2010. The global diversion of pharmaceutical drugs non-medical use and diversion of psychotropic prescription drugs in north america: A review of sourcing routes and control measures. Addiction 105(12): 2062–2070.CrossRefGoogle Scholar
  43. 43.
    Harrison, A.G., M.J. Edwards, and K.C.H. Parker. 2007. Identifying students faking ADHD: Preliminary findings and strategies for detection. Archives of Clinical Neuropsychology 22(5): 577–588.CrossRefGoogle Scholar
  44. 44.
    Booksh, R.L., R.D. Pella, A.N. Singh, and W.D. Gouvier. 2010. Ability of college students to simulate ADHD on objective measures of attention. Journal of Attention Disorders 13(4): 325–338.CrossRefGoogle Scholar
  45. 45.
    Sullivan, B.K., May Kim, and L. Galbally. 2007. Symptom exaggeration by college adults in attention-deficit hyperactivity disorder and learning disorder assessments. Applied Neuropsychology 14(3): 189–207.CrossRefGoogle Scholar
  46. 46.
    Mittenberg, W., C. Patton, E.M. Canyock, D.C. Condit, and W. Mittenberg. 2002. Base rates of malingering and symptom exaggeration. Journal of Clinical and Experimental Neuropsychology. 24(8): 1094–1102.CrossRefGoogle Scholar
  47. 47.
    Soliman, M.J., J.D. Ranseen, T. David, and R. Berry. 2010. Detection of feigned ADHD in college students. Psychological Assessment. 22(2): 325–335.CrossRefGoogle Scholar
  48. 48.
    Greely, Henry, B. Sahakian, J. Harri, R.C. Kessler, M. Gazzaniga, P. Campbell, and Marth J. Farah. 2008. Towards responsible use of cognitiveenhancing drugs by the healthy. Nature 456: 702e5.CrossRefGoogle Scholar
  49. 49.
    Richmond, Vanessa and Cohen, Lindsay. Up All Night With New Study Aids. Available at http://www.straight.com/article/up-all-night-with-new-study-aids [accessed 13 June 2011].
  50. 50.
    Laurance, Jeremy. 2003. Ritalin abuse hits students looking for an exam kick. Available at: http://www.independent.co.uk/news/education/education-news/ritalin-abuse-hits-students-looking-for--an-exam-kick-537088.html [accessed 13 June 2011].
  51. 51.
    Hall, K.M., M.M. Irwin, K.A. Bowman, W. Frankenberger, and D.C. Jewett. 2005. Illicit use of prescribed stimulant medication among college students. Journal of American College Health 53(4): 167–174.CrossRefGoogle Scholar
  52. 52.
    Chadwick, Ruth Therapy, Enhancement and Improvement. In: Ruth Chadwick B. Gordijn, R. Chadwick (eds.) Medical Enhancement and Posthumanity. Springer Science & Business Media BV.Google Scholar
  53. 53.
    Daniels, N. 2000. Normal functioning and the treatment-enhancement distinction. Cambridge Quarterly of Healthcare Ethics 9(3): 309–322.CrossRefGoogle Scholar
  54. 54.
    Rasmussen, N. 2006. Making the First Anti-Depressant: Amphetamine in American Medicine, 1929–1950. Journal of The History Of Medicine and Allied Sciences 61(3): 288–323.CrossRefGoogle Scholar
  55. 55.
    Canu, W.H., M.L. Newman, T.L. Morrow, and Daniel L .W. Pope. 2008. Social appraisal of adult ADHD. Journal of Attention Disorders 11(6): 700–710.CrossRefGoogle Scholar
  56. 56.
    Inciardi, James A., Hilary L. Surratt, Steven P. Kurtz, and Theodore J. Cicero. 2007. Mechanisms of prescription drug diversion among drug-involved club and street-based populations. Pain Medicine 8(2): 171–183.Google Scholar
  57. 57.
    Downie, J., S. Outram, and F. Campbell. 2010. Caveat Emptor, Venditor, Et Praescribor: Legal Liability Associated With Methyplenidate Hydrochloride (MPH) Use By Postsecondary Students. Health Law Journal 18: 51–71.Google Scholar
  58. 58.
    Forlini, Cynthia and E. Racine. 2009. Autonomy and Coercion in Academic “Cognitive Enhancement” Using Methylphenidate: Perspectives of Key Stakeholders Neuroethics 2:163–177.Google Scholar
  59. 59.
    Hall, W. 2004. Feeling 'better than well'. EMBO Reports 5(12): 1105–1109.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Novel Tech EthicsDalhousie UniversityHalifaxCanada

Personalised recommendations